Science

Varda: Manufacturing medicine in space

A potential cancer drug is being manufactured in tiny capsules 300 miles above us, paving the way for an ambitious chapter in pharmaceutical science: medicine manufacturing in space. These capsules, being barely washing-machine sized, are growing crystals with potential cancer treatment. Varda Space Industries is a US-based company responsible for this development.

In October 2026, Varda launched three spacecraft into orbit, one of which is investigating the crystallization of a potential cancer drug while the other two are testing heat-protection materials and navigation systems for their eventual return to Earth. Being the only company to simultaneously launch three spacecraft in orbit, they are now on a mission to operate a fleet of orbiting pharmaceuticals dedicated to drug development in microgravity.

Why take medicine development to space?

Microgravity is a condition of nearweightlessness experienced in space, which drives this research. Gravity on Earth causes particles in liquid to settle, leading to sedimentation. Density differences create currents, causing convention. Both events can interfere with crystal formation, and removal of space can reduce their influence, allowing a more uniform crystal growth. The implications of this research are huge. A drug’s stability, solubility and administration method are determined by the arrangement, shape and size of these crystals. Current therapeutics which require intravenous infusions may be replaced by more convenient injections, opening a new avenue for pharmaceutical companies.

The technology behind Varda’s Achievements

Varda has developed autonomous spacecrafts known as ‘free-flyers’. These allow research to take place without astronauts, by carrying miniature laboratories into orbit aboard SpaceX rockets. Once the experiment is complete, the capsule separates from the spacecraft and plunges into the Earth’s atmosphere to an uninhabited landing site. Aiming to accelerate drug development in space, Varda has further planned seven such missions in 2027, and ten more in 2028.

Is space manufacturing becoming an industry?

Varda is not the only company delving in space research. Microgravity experiments have been conducted in the International Space Station (ISS) for decades, though it served as a testing environment and is scheduled to retire around 2030. UKbased BioOrbit is developing spacebased production of injectable cancer medicines, while Cardiff-based Space Forge is investigating the manufacture of semiconductor materials in orbit.

Can it actually work?

Launching spacecraft and recovering their contents is expensive, posing a hurdle. However, the benefits of microgravity research might justify these costs. Regulators would have to establish how existing medicines legislation applies to products manufactured in orbit. More importantly, companies would have to ensure that their processes deliver consistently reliable results across repeated missions.

The challenge is no longer simply whether we can manufacture drugs in space, but whether we can do so reliably, affordably and at a scale that makes a difference on Earth.

For now, pharmaceutical factories in orbit are an emerging prospect. As commercial launches increase in frequency and companies improve their manufacturing processes, the vision of producing medicines beyond Earth may become increasingly tangible. The challenge is no longer simply whether we can manufacture drugs in space, but whether we can do so reliably, affordably and at a scale that makes a difference on Earth.

From Issue 1909

20 November 2026

Discover stories from this section and more in the list of contents

Explore the edition